Moderna begins first late-stage US trial of Covid vaccine

Moderna has given the first doses of its experimental Covid-19 vaccine to participants in what will be a 30,000-person trial, as the US moved into a new phase in the race to develop a vaccine by the start of next year. The Boston-based biotech on Monday said it had begun the first phase-three study of a vaccine in the US, a large-scale trial that is usually the last before a new product is submitted for regulatory approval. The company’s shares were up as much as 10.6 per cent before paring some of their gains.